Arabic Arabic English English French French German German

Model-Integrated Evidence for Generic Drug Development – Session 1C

Presenters and a panel discuss exploring opportunities and challenges for utilizing artificial intelligence (e.g., machine learning and natural language processing) to support generic drug development and application assessment. Presentation titles include, “Artificial Intelligence in Pharmaceutics,” and “Artificial Intelligence in Generic Drug Development – Experience and Opportunities,” and “Improving Generic Drugs and Streamlining Their Approval Through Artificial Intelligence.”
Learn more at:
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training –   
SBIA Listserv –
SBIA 2021 Playlist –
SBIA LinkedIn –  
SBIA Training Resources –  
Twitter –  
Email –  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Model-Integrated Evidence for Generic Drug Development – Session 1B

Next Post

Complex Product Characterization/Analysis – Session 2A

Related Posts